ogyhejowy.wordpress.com
Hematide is in a Phasse III trial. Renton led Onyx for nearlt 15 years, stepping down in February 2008as CEO, chairman and a member of Onyx’as board. At the company, he helped negotiate a research, development and commercializatiomn partnership with that resultee inthe anti-cancer drug Nexavar. Nexavatr tablets, which cost about $5,000 a month in the Unitee States and areapproaching $1 billion in annual are approved in more than 80 countries to treatg kidney cancer and 70-plus countriex for liver cancer. Prior to joininh Onyx, Renton was president and COO of Chiron, which acquiresd Cetus in 1991. Renton had been presidenrt of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987.
Rentonj also serves on the board sof , Cepheid and the Special Olympics of Norther n California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment